Skip to main content

IP Update: Mar 12, 2009

Premium

Title: Ii-RNAi-Involved Ii Suppression in Cancer Immunotherapy

Number: 20090060889

Filed: March 10, 2008

Lead Inventor: Eric von Hofe, Generex Biotechnology

The patent application, its abstract states, claims "compositions and methods involving the inhibition of Ii expression in cells for the purpose of altering antigen-presentation pathways.

"Human Ii-RNAi constructs that effectively inhibit Ii expression in human cancer cells have been generated," it notes. "The combination of different Ii-RNAi constructs that target different positions of Ii mRNA has a synergistic effect on Ii inhibition. Furthermore, specific promoters for driving Ii-RNAi expression are critical for the activity of Ii-RNAi in different types of cells. Active Ii-RNAi sequences were cloned into plasmids in which Ii-RNAi sequences are driven by either a CMV or an EF-1alpha promoter."

The application further claims "compositions and methods … for inhibiting Ii and treating cancer," the abstract states. "Provided are siRNAs and expression constructs comprising DNA sequences [that] encode siRNAs effective to inhibit Ii expression, cells containing such DNA constructs or siRNAs, and methods for use of the same."


Title: Devices, Systems, and Methods for Improving Memory and/or Cognitive Function Through Brain Delivery of siRNA

Number: 20090060987

Filed: Oct. 31, 2007

Inventor: William Kaemmerer, Medtronic

The invention, the patent application's abstract states, "relates to devices, systems, and methods for improving memory and/or cognitive function by brain delivery of compositions of small interfering RNA or vectors containing the DNA encoding for small interfering RNA. Such compositions can be administered using devices, systems, and methods for direct delivery of the compositions to the brain, or using devices, systems, methods of delivery, and compositions that deliver small interfering RNA or vectors containing the DNA encoding the small interfering RNA across the blood-brain barrier. The … invention also provides valuable small interfering RNA vectors, and methods for reduction of BACE1 levels in the hippocampus, cerebral cortex, or other regions of the brain that have beneficial effects on improving memory and/or cognitive function in a subject."


Title: Cancer-Cell Targeting Using Nanoparticles

Number: 20090061010

Filed: March 31, 2008

Lead Inventor: Stephen Zale, Massachusetts Institute of Technology

The invention "generally relates to polymers and macromolecules, in particular, to polymers useful in particles such as nanoparticles," the patent application's abstract states. "One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. In some cases, the nanoparticle may contain a drug. Other aspects of the invention are directed to methods using nanoparticle libraries."


Title: siRNA and Methods of Manufacture

Number: 20090061487

Filed: Sept. 6, 2007

Lead Inventor: Sam Reich, Opko Health

The patent application, its abstract states, claims "double-stranded RNA of about 19 to about 25 nucleotides in length capable of regulating gene expression by RNA interference. … Such double-stranded RNA are particularly useful for treating disease or conditions associated with a target mRNA or gene. Methods of manufacture and methods of use of the double-stranded RNA are also provided."


Title: Compositions and Methods for Inhibiting Expression of a Gene from the JC Virus

Number: 20090062225

Filed: April 27, 2007

Lead Inventor: Pamela Tan, Alnylam Pharmaceuticals

According to the patent application's abstract, the invention "relates to a double-stranded ribonucleic acid for inhibiting the expression of a gene from the JC virus comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a gene from the JC virus. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by JC-virus expression and the expression of a gene from the JC virus using the pharmaceutical composition; and methods for inhibiting the expression of a gene from the JC virus in a cell."


Title: piRNA and Uses Related Thereto

Number: 20090062228

Filed: March 7, 2008

Lead Inventor: Greg Hannon, Cold Spring Harbor Laboratory

"The invention relates to small single stranded RNAs and analogs thereof, collectively "piRNA" herein, compositions comprising such piRNAs, and their uses in regulating target-gene expression or as markers for certain disease states," the patent application's abstract states.



Title:
Method and Composition for Reducing the Expression of ROCK-II

Number: 20090062229

Filed: May 6, 2008

Lead Inventor: Scott Morham, Myriad Genetics

The patent application, its abstract states, claims "methods and compositions for reducing the expression of Rho-associated, coiled-coil containing protein kinase 2." The application specifically claims RNAi-based methods of reducing ROCK-II expression.



Title:
Creating Poultry and Other Animals Resistant to Viral Disease

Number: 20090064352

Filed: March 31, 2006 PCT Filed: March 31, 2006

Inventor: Ronen Kahana, Kimron Veterinary Institute

The invention, the patent application's abstract states, "is directed to genetically modified animals … resistant to viral infections," and claims "methods for creating animals which are resistant to viral infections."

The application specific claims the use of siRNAs to create the animals.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.